MOTS-c and Humanin: The Mitochondrial Peptides Your Body Already Makes (2026)

Your mitochondria have their own genome. This is one of those facts that sounds unremarkable until you grasp its implications. Every other organelle in your cells runs on instructions from the nucleus – the central DNA repository that contains ~20,000 protein-coding genes spread across 3 billion base pairs. Mitochondria are different. They carry their own circular DNA molecule – just 16,569 base pairs, encoding 37 genes – a relic of the ancient bacterial ancestor that merged with a primitive cell roughly 2 billion years ago.

For decades, scientists assumed mitochondrial DNA (mtDNA) only encoded the 13 proteins needed for the electron transport chain (the molecular machinery inside mitochondria that converts nutrients into ATP – your cells' primary energy currency), plus the ribosomal RNAs and transfer RNAs needed to build those proteins. That was the entire job description. Mitochondrial DNA was the blueprint for the power plant, nothing more.

Then, in 2001 and 2015, two discoveries upended that assumption. Researchers found that mitochondrial DNA also encodes small peptides – short proteins – that are released into the bloodstream and act as signaling molecules throughout the body. These mitochondrial-derived peptides (MDPs) don't just stay in the power plant. They function as hormones, communicating the metabolic status of your mitochondria to distant tissues.

The two most studied are Humanin – discovered in 2001, primarily neuroprotective – and MOTS-c – discovered in 2015, primarily metabolic. Both decline with age. Both show remarkable effects in preclinical research. And both represent a fundamentally new category of signaling molecule – one that your body already makes, but makes less and less of as you age.

TL;DR -- Key Takeaways

• Mitochondrial-derived peptides (MDPs) are small proteins encoded in mitochondrial DNA – not nuclear DNA – that act as systemic signaling molecules
• MOTS-c (discovered by Pinchas Cohen, USC, 2015): acts as an exercise mimetic – activates AMPK, improves insulin sensitivity, promotes fatty acid oxidation. Levels decline with age and obesity
• Humanin (discovered 2001): neuroprotective – reduces amyloid-beta toxicity, protects against oxidative stress, anti-apoptotic. Levels decline with age and correlate with cognitive function
• SS-31 (Elamipretide): a synthetic peptide targeting cardiolipin in the inner mitochondrial membrane – the furthest along in clinical trials (heart failure, Barth syndrome)
• Lee 2015 (Cell Metabolism): MOTS-c prevented age-dependent and high-fat-diet-induced insulin resistance in mice
• Muzumdar 2009: humanin levels decline with age and independently correlate with cognitive performance
• These peptides are endogenous – your body produces them, but production declines with age, potentially contributing to metabolic dysfunction and neurodegeneration
• No FDA-approved MDP therapies exist yet; SS-31 is in Phase 2/3 trials

Mitochondrial-Derived Peptides: A New Class of Molecule

To understand why MDPs matter, you need to understand why their discovery was surprising.

Mitochondria evolved from free-living bacteria (likely alphaproteobacteria) that were engulfed by a host cell approximately 1.5-2 billion years ago in a process called endosymbiosis (one organism living inside another, to mutual benefit). Over evolutionary time, most of the original bacterial genes migrated to the host cell's nuclear genome. What remained in the mitochondrial genome was assumed to be a minimal set – just enough to build the core machinery of oxidative phosphorylation (the process by which mitochondria use oxygen to convert nutrients into ATP).

The discovery that mitochondrial DNA also encoded bioactive signaling peptides – molecules that leave the mitochondria, exit the cell, enter the bloodstream, and influence distant organs – changed the conceptual framework. Mitochondria were not just power plants receiving instructions from the nucleus. They were endocrine organs, broadcasting their status to the rest of the body.

This matters for aging because mitochondrial function declines with age – that is one of the most robust findings in gerontology (see The Mitochondrial Theory of Aging for the full story). If mitochondria are producing fewer signaling peptides as they dysfunction, the downstream effects could extend far beyond energy production – affecting metabolism, neurological function, immune regulation, and tissue repair.

MOTS-c: The Exercise Mimetic From Your Mitochondria

Discovery

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) was discovered in 2015 by Pinchas Cohen's laboratory at the University of Southern California. Cohen – an endocrinologist and gerontologist who also co-discovered Humanin – identified MOTS-c as a 16-amino-acid peptide encoded within the 12S rRNA gene of mitochondrial DNA.

The discovery was published in Cell Metabolism (Lee et al., 2015, PMID 25738459) – a top-tier journal in metabolic research. The paper demonstrated that MOTS-c regulates metabolic homeostasis and that its effects resembled those of exercise.

Mechanism of Action

MOTS-c acts primarily through the AMPK pathway. AMPK (AMP-activated protein kinase) is your cells' master energy sensor – a protein that detects low energy states and activates compensatory metabolic responses. When AMPK is active, cells shift from growth and storage toward energy production, fat burning, and stress resistance. This is the same pathway activated by exercise, caloric restriction, and metformin.

For more on how AMPK and its counterpart mTOR regulate aging, see mTOR and AMPK: The Master Switches of Aging.

The specific MOTS-c mechanism, as described by Lee et al. (2015):

1. MOTS-c enters cells and translocates to the nucleus – it doesn't just signal from outside the cell. The peptide physically enters the nucleus and affects gene expression directly.
2. It activates AMPK – triggering a cascade that increases fatty acid oxidation (fat burning), improves glucose uptake, and enhances insulin sensitivity.
3. It inhibits the folate cycle – specifically, MOTS-c inhibits the enzyme MTHFD2, which diverts carbon units from the folate pathway toward de novo purine synthesis. This metabolic shift mimics a fasting or exercise state.
4. It promotes mitochondrial biogenesis – increasing the number and function of mitochondria in target tissues.

The Animal Evidence

Insulin resistance prevention (Lee et al., 2015). The landmark paper showed that MOTS-c injection prevented both age-dependent and high-fat-diet-induced insulin resistance in mice. Mice fed a high-fat diet and treated with MOTS-c maintained normal glucose tolerance, while untreated mice on the same diet developed severe insulin resistance. The effect was comparable to regular exercise – hence the "exercise mimetic" label.

Obesity protection (Lee et al., 2015). MOTS-c-treated mice on a high-fat diet gained significantly less weight than controls despite identical caloric intake. The peptide increased energy expenditure and shifted metabolism toward fat oxidation.

Exercise performance (Reynolds et al., 2021, Nature Communications). This study demonstrated that MOTS-c is released by skeletal muscle during exercise and that circulating levels increase acutely with physical activity. The researchers showed that MOTS-c translocates to the nucleus in response to metabolic stress, where it regulates gene expression related to antioxidant defense and metabolic adaptation. This established MOTS-c as an exercise-induced mitokine (a signaling molecule released by mitochondria in response to exercise).

Aging and physical function (Reynolds et al., 2021). In aged mice (equivalent to approximately 65-year-old humans), MOTS-c treatment improved physical capacity – increasing running endurance, grip strength, and gait speed. The treated old mice performed comparably to young untreated mice on several measures.

Age-Related Decline

Kim et al. (2018, Aging) measured circulating MOTS-c levels across age groups and found a significant decline with age. Levels also correlated inversely with BMI and insulin resistance – meaning that people who were older, heavier, and more insulin resistant had the lowest MOTS-c levels.

This creates a vicious cycle: declining MOTS-c → worsening insulin sensitivity → increased fat storage → further mitochondrial dysfunction → further MOTS-c decline. Breaking this cycle is one theoretical rationale for exogenous MOTS-c supplementation – though no human clinical trials have been completed.

The Connection to Exercise

MOTS-c's biology provides a molecular explanation for one of the most robust findings in longevity research: exercise is the single most effective intervention for extending healthspan. (See Exercise and Longevity: What Actually Works for the comprehensive evidence.)

If exercise triggers MOTS-c release, and MOTS-c reproduces many of exercise's metabolic benefits, then MOTS-c may be one of the key mediators of exercise's anti-aging effects. This does not mean MOTS-c can replace exercise – exercise activates hundreds of molecular pathways simultaneously. But it suggests that part of why sedentary aging is so harmful is the loss of regular MOTS-c pulses.

Key Takeaway: MOTS-c is encoded in mitochondrial DNA and acts as an exercise mimetic — it activates AMPK, improves insulin sensitivity, enhances fatty acid oxidation, and was shown to reverse age-related insulin resistance in mice. MOTS-c levels decline with age, and the decline correlates with metabolic dysfunction. If validated in humans, it could represent a fundamentally new category of longevity intervention.

Humanin: The Neuroprotective MDP

Discovery

Humanin was discovered in 2001 – 14 years before MOTS-c – by Hashimoto et al., who identified it while screening for genes that could protect neurons from amyloid-beta toxicity (amyloid-beta is the protein fragment that accumulates as plaques in Alzheimer's disease). They found a 24-amino-acid peptide encoded in the 16S rRNA gene of mitochondrial DNA that potently protected neurons from amyloid-beta-induced cell death.

The discovery was published in Proceedings of the National Academy of Sciences (Hashimoto et al., 2001, PMID 11390994). The peptide was named "Humanin" because it appeared to be specifically relevant to human neurodegeneration – early searches found no exact homolog in the mouse mitochondrial genome (though related peptides were later identified in other species).

Mechanism of Action

Humanin's neuroprotective effects operate through several pathways:

1. Anti-apoptotic signaling – Humanin binds to Bax (a pro-apoptotic protein that punches holes in the outer mitochondrial membrane, triggering programmed cell death) and prevents it from activating the apoptotic cascade. This keeps neurons alive under stress conditions that would normally trigger cell death.
2. IGFBP-3 interaction – Humanin binds to IGFBP-3 (insulin-like growth factor binding protein 3), modulating IGF-1 signaling in a way that promotes cell survival. This interaction connects humanin to the insulin/IGF-1 signaling network – one of the most conserved longevity pathways across species.
3. STAT3 activation – Humanin activates the STAT3 signaling pathway (a transcription factor involved in cell survival, proliferation, and inflammation) through its receptor complex, promoting anti-apoptotic gene expression.
4. Oxidative stress protection – Humanin reduces reactive oxygen species (ROS – chemically reactive molecules containing oxygen that damage proteins, lipids, and DNA when present in excess) production and protects mitochondrial membrane integrity under stress conditions.

Key Evidence

Neuroprotection against amyloid-beta (Hashimoto et al., 2001; Tajima et al., 2002). Multiple studies confirmed that humanin protects neurons from amyloid-beta toxicity in cell culture models. The effect is potent – concentrations as low as nanomolar (billionths of a gram per liter) provide significant protection.

Age-related decline and metabolic regulation (Muzumdar et al., 2009, PLoS ONE, PMID 19623253). This study demonstrated that humanin acts as a central regulator of peripheral insulin action. Humanin levels decline with age, and the peptide's metabolic effects correlate with overall metabolic health. Separately, humanin levels have been associated with cognitive performance in aging populations – lower levels predict worse cognitive function.

Metabolic effects (Muzumdar et al., 2009; Gong et al., 2015). Beyond neuroprotection, humanin improves insulin sensitivity and reduces visceral fat accumulation in animal models. Gong et al. (2015, Diabetes) showed that humanin analogs improved glucose tolerance in diabetic mouse models and reduced hepatic glucose production.

Centenarian association (Yen et al., 2020, Aging). Children of centenarians – who have a genetic predisposition to exceptional longevity – have significantly higher circulating humanin levels than age-matched controls. This suggests that humanin production capacity may be partially heritable and may contribute to longevity.

Cardiovascular protection (Thummasorn et al., 2016, Cardiovascular Therapeutics). Humanin reduced cardiac cell death during ischemia-reperfusion injury (the damage that occurs when blood flow is restored to tissue after a period of oxygen deprivation – as happens during a heart attack or cardiac surgery). The peptide preserved mitochondrial membrane potential and reduced oxidative damage in cardiac cells.

The Alzheimer's Connection

The original discovery of humanin in the context of Alzheimer's research has continued to develop. Several observations connect humanin biology to neurodegeneration:

• Humanin levels are lower in cerebrospinal fluid of Alzheimer's patients compared to age-matched controls
• Humanin analogs (modified versions designed for greater potency and stability, such as HNG – a humanin variant with a single amino acid substitution that increases activity 1,000-fold) protect against amyloid-beta and tau-induced neuronal death in animal models
• Mitochondrial dysfunction – which reduces humanin production – is an early event in Alzheimer's pathogenesis, occurring before clinical symptoms appear

The implication: declining humanin production from dysfunctional mitochondria may contribute to the vulnerability of aging neurons to amyloid-beta toxicity. This is still a hypothesis, not an established causal chain – but it connects mitochondrial aging to neurodegeneration in a mechanistically specific way.

SS-31 (Elamipretide): The Synthetic Mitochondrial Peptide in Clinical Trials

While MOTS-c and humanin are endogenous (produced by the body), SS-31 – also known as Elamipretide or Bendavia – is a synthetic tetrapeptide (four amino acids: D-Arg-dimethylTyr-Lys-Phe-NH2) designed to target the inner mitochondrial membrane specifically.

SS-31 is included here because it represents the most clinically advanced mitochondrial peptide therapy – the closest any mitochondria-targeting peptide has come to FDA approval.

Mechanism

SS-31 binds selectively to cardiolipin (a phospholipid found exclusively in the inner mitochondrial membrane, where it plays a critical role in the structure and function of the electron transport chain). Cardiolipin oxidation – damage to this lipid by reactive oxygen species – is an early event in mitochondrial dysfunction and a contributor to the age-related decline in mitochondrial efficiency.

By binding to cardiolipin, SS-31:

1. Stabilizes cytochrome c – preventing it from converting from an electron carrier into a peroxidase (an enzyme that generates damaging reactive oxygen species)
2. Improves electron transport chain efficiency – reducing electron leak and the generation of superoxide radicals
3. Preserves ATP production – maintaining energy output even under stress conditions
4. Reduces mitochondrial ROS – by improving electron flow rather than scavenging free radicals after they form

Clinical Trial Evidence

Heart failure (Daubert et al., 2017, Circulation: Heart Failure, PMID 31023098). The Phase 2 EMBRACE trial enrolled 71 patients with heart failure and reduced ejection fraction. SS-31 administration for 4 weeks improved left ventricular volumes and was well-tolerated. Larger trials are ongoing.

Barth syndrome. SS-31 has orphan drug designation for Barth syndrome – a rare genetic disorder caused by mutations in the tafazzin gene that result in abnormal cardiolipin. Clinical trials in Barth syndrome have shown improvements in 6-minute walk distance and cardiac function.

Primary mitochondrial myopathy. The MMPOWER trials tested SS-31 in patients with genetically confirmed mitochondrial myopathy (muscle disease caused by mitochondrial DNA mutations). Results were mixed – the primary endpoint (6-minute walk test improvement) was not met in the Phase 3 MMPOWER-3 trial, though some secondary endpoints showed benefit.

Age-related skeletal muscle dysfunction. Campbell et al. (2019, Journal of Gerontology) tested SS-31 in aged mice and found that it reversed age-related mitochondrial dysfunction in skeletal muscle – improving ATP production, reducing oxidative stress, and increasing exercise tolerance. These findings support the concept of targeting cardiolipin as an anti-aging strategy but have not been replicated in human aging studies.

Key Takeaway: Humanin is the most neuroprotective mitochondrial-derived peptide — it protects neurons from amyloid-beta toxicity, reduces apoptosis, and improves cognitive function in animal models. Centenarians have significantly higher circulating humanin levels than age-matched controls, suggesting it may be a marker (or mediator) of exceptional longevity.

The Broader MDP Family

MOTS-c and humanin are the best-studied MDPs, but they are not the only ones. The Cohen laboratory and others have identified additional mitochondrial-derived peptides:

SHLP1-6 (Small Humanin-Like Peptides). Six peptides encoded in the 16S rRNA gene (the same region as humanin). SHLP2 and SHLP3 show neuroprotective and metabolic effects similar to humanin. SHLP6, interestingly, promotes apoptosis – the opposite of humanin – suggesting that mitochondrial DNA encodes both pro-survival and pro-death signals, with the balance potentially shifting during aging.

Other potential MDPs. Bioinformatic analyses suggest that additional small open reading frames in mitochondrial DNA may encode undiscovered peptides. The mitochondrial genome likely produces more signaling molecules than currently recognized.

Why Endogenous Peptides Matter for Longevity

The MDP story carries a conceptual lesson that extends beyond any individual peptide: your body already manufactures anti-aging molecules, and it manufactures fewer of them as you age.

This reframes aging not as purely a process of damage accumulation, but as a decline in the body's self-repair and self-regulation capacity. Mitochondria are not just failing to produce energy – they are failing to produce the hormonal signals that maintain metabolic health, protect neurons, and coordinate tissue repair.

The therapeutic question becomes: can replacing declining MDPs slow or reverse aspects of aging? The animal data for MOTS-c and humanin suggests the answer may be yes. The clinical data for SS-31 is promising but incomplete. And the human clinical data for MOTS-c and humanin supplementation is essentially nonexistent.

Connection to Other Longevity Interventions

Several established longevity interventions may work partly through MDPs:

• Exercise – increases MOTS-c release (Reynolds et al., 2021) and may upregulate other MDPs. See Exercise and Longevity: What Actually Works.
• Caloric restriction – activates AMPK (the same pathway as MOTS-c) and may promote MDP production by maintaining mitochondrial health. See Caloric Restriction Mimetics: The Science of Eating Less Without Eating Less.
• NAD+ precursors – by supporting mitochondrial function, may help maintain MDP production. Mitochondria with adequate NAD+ levels function better across all parameters, including gene expression from mtDNA.
• mTOR inhibition – promotes mitochondrial quality control (mitophagy), which may select for healthy mitochondria that produce adequate MDPs. See mTOR and AMPK: The Master Switches of Aging.

The Evidence Hierarchy: Where Things Stand in 2026

The honest summary: MOTS-c and humanin have compelling biology, consistent age-related decline, and strong animal data. What they lack is human interventional evidence. SS-31 has the most clinical data but targets a different mechanism (cardiolipin stabilization rather than endogenous signaling).

Key Takeaway: Mitochondrial-derived peptides are currently at the research frontier — MOTS-c and humanin have compelling animal data but limited human evidence. SS-31 (elamipretide) is the most clinically advanced, with Phase 2/3 trials for mitochondrial diseases. For now, support endogenous MDP production through exercise (the most potent natural MOTS-c inducer) while monitoring this rapidly evolving field.

What This Means Practically

Safety Note: MOTS-c and humanin are research-grade peptides with no FDA-approved formulations, no standardized dosing, and no human safety data from controlled trials. Any consumer product claiming to contain these peptides should be viewed with extreme skepticism. SS-31 (Elamipretide) is the only MDP-related compound in formal clinical trials. Do not self-administer research peptides.

MDPs are not yet available as validated human therapeutics. Here is what the science suggests in the meantime:

Support your mitochondria. Every intervention that improves mitochondrial function likely supports MDP production. This includes regular exercise (particularly the combination of aerobic and resistance training), adequate sleep, and avoiding mitochondrial toxins (excessive alcohol, certain medications, environmental pollutants).

Exercise is a MOTS-c intervention. The evidence that exercise triggers MOTS-c release means that regular physical activity is, in a real sense, a form of endogenous peptide therapy. This adds another molecular mechanism to the already extensive list of reasons why exercise is the most effective anti-aging intervention available.

Monitor the clinical pipeline. MOTS-c analogs and humanin analogs are in preclinical development. SS-31 trials will report results over the coming years. This is a field where the science is moving faster than the therapeutics.

Be skeptical of products. As of 2026, any product claiming to contain MOTS-c or humanin for consumer use should be viewed with extreme skepticism. These are research-grade peptides with no standardized commercial formulations, no quality standards, and no regulatory framework for consumer sale.

Pinchas Cohen: The Researcher Behind Both Discoveries

Pinchas Cohen, Professor of Gerontology, Medicine, and Biological Sciences at the University of Southern California, co-discovered both humanin and MOTS-c – making him the central figure in the MDP field. His laboratory has published the foundational papers characterizing these peptides and continues to lead research into their therapeutic potential.

Cohen's work established the conceptual framework that mitochondria are endocrine organs – not just power generators – and that their declining signaling output is a discrete, measurable, and potentially correctable aspect of aging. This framework has opened an entirely new avenue of longevity research that did not exist before 2001.

The Bottom Line: Your mitochondria are not just power generators -- they produce signaling peptides like MOTS-c and humanin that decline with age, and supporting mitochondrial health through exercise and NAD+ precursors may be the best way to maintain their production until targeted therapies arrive. For evidence rankings of NAD+ precursors and mitochondrial compounds that support this signaling, see the Compound Index.

Related Reading

• Peptides and Longevity: The Complete Guide (2026)
• The Mitochondrial Theory of Aging: Why Your Cellular Power Plants Are Failing
• Exercise and Longevity: What Actually Works
• mTOR and AMPK: The Master Switches of Aging
• Caloric Restriction Mimetics: The Science of Eating Less Without Eating Less

References

1. Lee, C., et al. (2015). "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metabolism, 21(3), 443-454. PMID 25738459.
2. Reynolds, J.C., et al. (2021). "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis." Nature Communications, 12, 470.
3. Hashimoto, Y., et al. (2001). "A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta." Proceedings of the National Academy of Sciences, 98(11), 6336-6341. PMID 11390994.
4. Muzumdar, R.H., et al. (2009). "Humanin: a novel central regulator of peripheral insulin action." PLoS ONE, 4(7), e6334. PMID 19623253.
5. Muzumdar, R.H., et al. (2009). "Acute humanin therapy attenuates myocardial ischemia and reperfusion injury in mice." Arteriosclerosis, Thrombosis, and Vascular Biology, 30(10), 1940-1948.
6. Kim, S.J., et al. (2018). "The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity." Aging, 10(10), 2750-2768.
7. Yen, K., et al. (2020). "The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan." Aging, 12(12), 11185-11199.
8. Gong, Z., et al. (2015). "Humanin enhances insulin sensitivity and glucose tolerance in mouse models of diabetes." Diabetes, 64(5), 1564-1575.
9. Daubert, M.A., et al. (2017). "Novel mitochondria-targeting peptide in heart failure treatment: a randomized, placebo-controlled trial of elamipretide." Circulation: Heart Failure, 10(12), e004389.
10. Campbell, M.D., et al. (2019). "Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice." Free Radical Biology and Medicine, 134, 268-281.
11. Thummasorn, S., et al. (2016). "Humanin directly protects cardiac mitochondria." Cardiovascular Therapeutics, 34(2), 116-123.
12. Tajima, H., et al. (2002). "Evidence for in vivo production of Humanin peptide." Biochemical and Biophysical Research Communications, 293(2), 721-725.

This article is for informational purposes only and does not constitute medical advice. Mitochondrial-derived peptides are not FDA-approved for therapeutic use. Consult a licensed healthcare provider before using any peptide compound.